about
Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the SpotPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaDysregulation of skeletal muscle protein metabolism by alcoholHeterogeneity of epidermal growth factor receptor signalling networks in glioblastomaO-GlcNAcylation and Metabolic Reprograming in CancerInhibition of mTORC1 Enhances the Translation of Chikungunya Proteins via the Activation of the MnK/eIF4E PathwayStress responses from the endoplasmic reticulum in cancerMechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative diseaseModulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cellsCancer metabolism as a central driving force of glioma pathogenesismTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.Significance of filamin A in mTORC2 function in glioblastomaReplication of the Shrimp Virus WSSV Depends on Glutamate-Driven Anaplerosis.Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells.mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cellsHepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein InhibitionCharacterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells.Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.Regulation of innate immune cell function by mTOR.Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line.Melanocytic nevi and melanoma: unraveling a complex relationship.Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors.Glutamate and α-ketoglutarate: key players in glioma metabolism.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12).HIF1α and metabolic reprogramming in inflammation.Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.Na+ influx via Orai1 inhibits intracellular ATP-induced mTORC2 signaling to disrupt CD4 T cell gene expression and differentiation.Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake.Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation.Molecular and Genetic Determinants of Glioma Cell Invasion.Emerging functions of the EGFR in cancer.Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.Metabolic advantages and vulnerabilities in brain metastases.Large Intergenic Non-coding RNA-RoR Inhibits Aerobic Glycolysis of Glioblastoma Cells via Akt Pathway.
P2860
Q26748629-39C77EE6-591C-4393-9BB3-329A6C42ECB7Q26766293-13A27D8C-25D5-4E5B-B8B0-EAE7920ACDC8Q26826554-474EB986-CADE-4D2F-A643-0BF2C4BC1DEAQ27013006-CE44CBE5-F06C-4B2B-989D-5F1847448691Q27027028-32FB8043-0674-4A14-838F-0C60495ADA84Q27318237-8C410771-745F-4179-AF26-994E769BB69EQ28082709-ED37775B-AAF7-4E25-90B6-1623D2F5EE75Q28394732-A067DD03-8E8C-4D6E-857D-308F4CA96F91Q28544009-424DE0DD-A1B1-4492-9A3C-DFF6FD859103Q33847616-24893B70-8E9E-443A-A34E-E753ED617BF0Q33884658-BFB7E9E8-5210-4E9C-97FA-8F676BB4C6FBQ34974398-A1924E22-F02A-422C-96B4-F924CF8689C9Q35809950-730A5582-31C0-49D3-8E90-295D7C2384E9Q35890103-79391D91-77B8-470C-8891-8D78DD3C6FDBQ35910243-AF8076B1-B7C3-47A0-B428-C1130682C3A6Q36245893-FFD26852-2E2F-40B3-AA13-255DF56510E1Q36247876-9F4A0DF4-CBB4-454F-AC79-013636CB6B92Q36256815-01DA8FD3-4E54-4F59-91C9-B06ECC49355FQ36327268-3164F490-E497-4D74-8F6B-75CF6979B5EEQ36419236-E920C3FD-D6A8-479F-926A-109625E0492FQ36570461-D84AE457-BCD1-447A-B1AD-3165EDB53B86Q36650365-C704ECE6-5511-438C-A511-9C2D3DD3C75BQ37687122-FE2DCE5E-3254-4D4F-8AE0-C8CD6363B1ADQ38592317-584EA923-32A0-4176-A65B-1F85525756BCQ38715697-DBFD06F0-1FD1-48CE-BBFB-A653BBCFC2B5Q38730348-20FDD474-4C71-4A1F-B5BB-289DF8E50A8DQ38978340-6585AB84-D4F5-4E3C-86E1-6908C236A55BQ38983559-DA1ADD36-8853-42DA-B1BA-95491160F9AEQ39107981-489B3373-1762-415C-89AB-9F4DAF3FADC5Q40961859-22DF9E65-AD24-4C41-B875-1F69134ACC47Q41678886-C5931E85-08B1-4085-AE4A-2D038B04208EQ41781449-5FBEAEFC-ED13-4AD3-A9DF-A2679E47664CQ41993905-4A2065B0-506F-4647-9B0F-1D9A080CD6C7Q42216316-68B55489-EFA9-4E22-9A65-920BC5B5CE1AQ42339950-7A24730D-1AD9-4D64-AD6B-5B437E13A162Q46594099-CA704DB8-9AB3-45E1-9F82-D79D0309F8F3Q47124344-BB3FC530-6F8C-4EBA-95AF-17538D2EAC44Q47132331-FCEDB1BB-06D0-4E4C-A2A8-809F0638243FQ47566658-EAF9A7B1-0130-4461-BF9D-C3BF1918D93CQ52340921-270D22A8-D07F-4138-814C-313ECC919902
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
mTORC2 in the center of cancer metabolic reprogramming
@ast
mTORC2 in the center of cancer metabolic reprogramming
@en
type
label
mTORC2 in the center of cancer metabolic reprogramming
@ast
mTORC2 in the center of cancer metabolic reprogramming
@en
prefLabel
mTORC2 in the center of cancer metabolic reprogramming
@ast
mTORC2 in the center of cancer metabolic reprogramming
@en
P2093
P2860
P1476
mTORC2 in the center of cancer metabolic reprogramming
@en
P2093
Kenta Masui
Paul S Mischel
Webster K Cavenee
P2860
P304
P356
10.1016/J.TEM.2014.04.002
P577
2014-05-21T00:00:00Z